Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Johnson and Johnson
Fuji
Federal Trade Commission
Medtronic
Moodys
Dow
Boehringer Ingelheim
QuintilesIMS

Generated: September 20, 2018

DrugPatentWatch Database Preview

Perrigo Pharma Intl Company Profile

« Back to Dashboard

What is the competitive landscape for PERRIGO PHARMA INTL, and what generic alternatives to PERRIGO PHARMA INTL drugs are available?

PERRIGO PHARMA INTL has thirteen approved drugs.

There are three US patents protecting PERRIGO PHARMA INTL drugs.

Summary for Perrigo Pharma Intl
US Patents:3
Tradenames:8
Ingredients:8
NDAs:13

Drugs and US Patents for Perrigo Pharma Intl

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Perrigo Pharma Intl LORATADINE AND PSEUDOEPHEDRINE SULFATE loratadine; pseudoephedrine sulfate TABLET, EXTENDED RELEASE;ORAL 076050-001 Jan 30, 2003 OTC No No ➤ Try a Free Trial ➤ Try a Free Trial
Perrigo Pharma Intl TRETINOIN tretinoin GEL;TOPICAL 075589-001 Jun 11, 2002 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Perrigo Pharma Intl EVAMIST estradiol SPRAY;TRANSDERMAL 022014-001 Jul 27, 2007 RX Yes Yes 6,978,945 ➤ Try a Free Trial Y ➤ Try a Free Trial
Perrigo Pharma Intl LORATADINE loratadine TABLET, ORALLY DISINTEGRATING;ORAL 076011-001 Sep 29, 2003 OTC No No ➤ Try a Free Trial ➤ Try a Free Trial
Perrigo Pharma Intl TRETINOIN tretinoin CREAM;TOPICAL 075213-001 Dec 24, 1998 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Perrigo Pharma Intl

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Perrigo Pharma Intl ENTOCORT EC budesonide CAPSULE;ORAL 021324-001 Oct 2, 2001 5,643,602*PED ➤ Try a Free Trial
Perrigo Pharma Intl BUTOCONAZOLE NITRATE butoconazole nitrate CREAM;VAGINAL 019881-001 Feb 7, 1997 4,078,071 ➤ Try a Free Trial
Perrigo Pharma Intl EVAMIST estradiol SPRAY;TRANSDERMAL 022014-001 Jul 27, 2007 6,299,900 ➤ Try a Free Trial
Perrigo Pharma Intl EVAMIST estradiol SPRAY;TRANSDERMAL 022014-001 Jul 27, 2007 6,923,983 ➤ Try a Free Trial
Perrigo Pharma Intl CLINDESSE clindamycin phosphate CREAM;VAGINAL 050793-001 Nov 30, 2004 5,993,856 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for PERRIGO PHARMA INTL drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Vaginal Cream 2% ➤ Subscribe 2015-02-05
➤ Subscribe Enteric Coated Capsules 3 mg ➤ Subscribe 2008-02-01

Supplementary Protection Certificates for Perrigo Pharma Intl Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2009 00017 Denmark ➤ Try a Free Trial PRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629
C0008 Belgium ➤ Try a Free Trial PRODUCT NAME: ESTRADIOL, HEMIHYDRATE; NAT. REGISTRATION NO/DATE: NL 19489 19941107; FIRST REGISTRATION: FR - NL 19489 19941107
C0002 Belgium ➤ Try a Free Trial PRODUCT NAME: ESTRADIOL; NAT. REGISTRATION NO/DATE: NL 18978 19960731; FIRST REGISTRATION: SE - 11783 19930305
2006 00038 Denmark ➤ Try a Free Trial PRODUCT NAME: ETHINYLESTRADIOL (SOM BETA-CYCLODEXTRIN-CLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 38687 20060627; FIRST REG. NO/DATE: EU RVG 31781 20050804
C/GB08/005 United Kingdom ➤ Try a Free Trial SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Express Scripts
Johnson and Johnson
Cipla
QuintilesIMS
Cerilliant
UBS
Deloitte
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.